BioCardia Inc (BCDA) Actualités

Form 8-K - Current report

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in...

Form 8-K - Current report

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities